Constantin Laurent Palm

Mr. Constantin Laurent Palm

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in European Journal of Heart Failure
Verified
Journal Article
Open access
SVSuzanne Nathalie Voorrips
Suzanne Nathalie Voorrips
CPConstantin Laurent Palm
Constantin Laurent Palm
HSHuitzilihuitl Saucedo-Orozco
Huitzilihuitl Saucedo-Orozco
BMBelend Mahmoud
Belend Mahmoud
ESElisabeth Marloes Schouten
Elisabeth Marloes Schouten
BWB. Daan Westenbrink
B. Daan Westenbrink
Aims: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiac performance and clinical outcomes in patients with heart failure, yet mechanisms underlying these beneficial effects remain incompletely understood. We sought to determine whether SGLT2i-induced improvements in cardiac function are dependent on increased cardiac oxidation of ketone bodies. Methods and results: We employed a mouse model with a cardiac-specific knock-out of the enzyme D-β-hydroxybutyrate dehydrogenase-1 (BDH1cko), rendering mice incapable of oxidizing the principal ketone body β-hydroxybutyrate in cardiomyocytes. Male BDH1cko and littermate controls underwent either permanent coronary artery ligation of the left anterior descending coronary artery to induce myocardial infarction (MI) or sham surgery. Two weeks after surgery, mice were randomized to 6 weeks of empagliflozin or vehicle treatment. Cardiac function was assessed using transthoracic echocardiography before and after treatment, and histological and molecular analyses were performed after sacrifice. Empagliflozin treatment resulted in a twofold increase in circulating ketone bodies. Mean infarct size (36 ± 4% of the left ventricle) was comparable among MI groups. In control mice, empagliflozin treatment resulted in a significant increase in left ventricular ejection fraction (LVEF) whereas LVEF remained stable in the vehicle treated group (ΔLVEF −1.1 ± 2.2% vs. 5.2 ± 1.5%, p < 0.05). Empagliflozin did not influence cardiac contractility in BDH1cko mice (ΔLVEF −5.9 ± 2.1% vs. −1.5 ± 2.8%, p = 0.213). Other echocardiographic, histological and molecular signatures of adverse myocardial remodelling were not affected by empagliflozin treatment. Conclusion: The beneficial effects of empagliflozin on cardiac contractility in post-MI heart failure are attenuated in mice which are incapable of oxidizing the ketone body β-hydroxybutyrate in their hearts. These findings suggest that enhanced cardiac ketone body oxidation contributes to the cardioprotective effects of SGLT2i.

Verified
Journal Article
Open access
PDF file
CPConstantin Laurent Palm
Constantin Laurent Palm
ISIrina Shalaurova
Irina Shalaurova
Margery ConnellyMargery Connelly
Margery Connelly
SBStephan Bakker
Stephan Bakker
BWB. Daan Westenbrink
B. Daan Westenbrink
RDRobin Dullaart
Robin Dullaart
Background: Heart failure (HF) features a shift in metabolism towards enhanced utilization of ketone bodies. While elevations in plasma natriuretic peptides represent a biochemical hallmark of HF, natriuretic peptides may promote lipolysis, thereby contributing to fatty acid availability for ketogenesis. Methods: We cross-sectionally tested to what extent fasting plasma total ketone bodies (measured using nuclear magnetic resonance spectroscopy) are associated with N-terminal pro-BNP (NT-proBNP; electrochemiluminescent sandwich immunoassay) in individuals with and without HF. Results: Among 6217 participants from the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study, 203 were identified with HF. NT-proBNP was four-fold and total ketone bodies were 25% higher in HF participants (each p < 0.001). In both participants with and without HF, total ketone body levels correlated with NT-proBNP (r = 0.116 and 0.185, respectively; p < 0.001). In multivariable linear regression analysis adjusted for relevant covariates, total ketone bodies remained associated with NT-proBNP in the whole cohort (std β = 0.08, p < 0.001), without a difference in participants with and without HF (p interaction: 0.52). Conclusion: This general population-based study reveals an independent association of fasting total body ketone bodies with plasma NT-proBNP. Our findings suggest that a metabolic defense mechanism could be operative, providing the myocardium with ketone bodies to meet its energy demands.

31 August 2026 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
CPConstantin Laurent Palm
Constantin Laurent Palm
NSNiels T. B. Scholte
Niels T. B. Scholte
LLLirong Lu
Lirong Lu
SKSabrina Abou Kamar
Sabrina Abou Kamar
BBBarbara M. Bakker
Barbara M. Bakker
BWB. Daan Westenbrink
B. Daan Westenbrink
Background: Elevated plasma ketone bodies (KBs) are linked to poor outcomes in heart failure (HF), yet the prognostic value of repeated KB measurements is uncertain. Objective: To study temporal changes in plasma KBs in HF patients in relation to prognosis. Methods: Plasma KBs were measured by nuclear magnetic resonance spectroscopy in 467 patients from the TRIUMPH study. Blood was obtained up to seven times during 1-year follow-up after HF hospitalization. Associations between serial KB measurements and the endpoint of death and HF rehospitalization were investigated by joint modeling. Similar analyses were conducted in the Bio-SHiFT study, including 397 chronic HF patients with up to 10 repeated blood samples during a median follow-up of 2.1 years. The endpoint in Bio-SHiFT was a composite of cardiovascular death, HF hospitalization, left ventricular device implantation and heart transplantation. Results: In TRIUMPH, median age was 74 years, 37% of patients were female and 82% were in NYHA class III/IV. Estimated KBs were continuously higher in the 185 (40%) patients reaching the combined endpoint. Hazard ratios (HR) (95% confidence interval [CI]) for the endpoint per doubling of total KBs (TKBs), acetone, and β-hydroxybutyrate were 2.10 (1.27–3.71), 1.62 (1.08–2.44) and 1.62 (1.22–2.23), respectively, at any time during follow-up after adjustment for clinical characteristics and NT-proBNP at baseline. In Bio-SHiFT, median age was 64 years, 28.5% of patients were female, and 124 (31.2%) patients reached the primary endpoint. KBs were higher in patients reaching the endpoint. The HR per doubling of TKB was 5.36 (95% CI 2.18–14.0) and 4.24 (31.4–5.95) for acetone. Conclusion: Serially measured KB levels were associated with adverse events in two independent HF cohorts. Patients with adverse events displayed consistently higher KBs, potentially reflecting ongoing metabolic stress.

27 August 2026 in ESC Heart Failure
Verified
Journal Article
Open access
CPConstantin Laurent Palm
Constantin Laurent Palm
BEBart J van Essen
Bart J van Essen
LBLukas Baumhove
Lukas Baumhove
RARidha I S Alnuwaysir
Ridha I S Alnuwaysir
MCMargery A Connelly
Margery A Connelly
BWB. Daan Westenbrink
B. Daan Westenbrink
Introduction: Ketone body levels are elevated in patients with heart failure (HF). Recently, plasma levels of ketone bodies have been associated with mortality in patients with HF. However, little is known about the biological processes active in patients with high levels of ketone bodies. The objective of this study was to investigate the features and prognosis of patients with HF with elevated β-hydroxybutyrate levels. Furthermore, we aimed to determine the specific biological processes that are active in these patients that may result in elevated levels of β-hydroxybutyrate. Methods: β-hydroxybutyrate concentrations were measured by nuclear magnetic resonance spectroscopy in plasma from 478 patients with HF from the BIOSTAT-CHF cohort. In addition, the concentrations of 1057 circulating proteins were measured by liquid chromatography–mass spectrometry. Differential expression and ingenuity pathway analyses were used to investigate which biological processes are associated with high levels of β-hydroxybutyrate. Cox regression was used to investigate the association of β-hydroxybutyrate with mortality and HF hospitalization. Mediation analysis was conducted to determine how much of the association between β-hydroxybutyrate and outcomes is statistically explained by these processes. Results: The cohort consisted mostly of male patients (64.2%), with equal proportions of HF with reduced ejection fraction and preserved ejection fraction. Elevated β-hydroxybutyrate levels were independently associated with higher heart rate, lower iron levels, and lower body mass index. Moreover, every doubling of β-hydroxybutyrate was associated with a 36.4% increase in mortality (unadjusted hazard ratio 1.364: 95% confidence interval 1.089–1.707). Even after accounting for known risk factors, the relationship remained highly robust (adjusted hazard ratio 1.389; 95% confidence interval 1.150–1.677). Differential expression and ingenuity pathway analyses revealed that higher β-hydroxybutyrate levels were associated with the upregulation of pathways associated with acute inflammation and cachexia, whereas lipogenic and anabolic pathways were down-regulated. Subsequent multiple mediation analysis showed that 76% of the association between β-hydroxybutyrate and mortality was explained by these pathways. Conclusions: Elevated β-hydroxybutyrate levels predict mortality in chronic HF, independent of established risk factors. Proteomic analysis links elevated β-hydroxybutyrate to heightened inflammation and catabolism, and these pathways largely mediated the association between β-hydroxybutyrate and mortality. These findings suggest that elevated ketone bodies may reflect underlying metabolic stress in patients at risk of adverse outcome.

1 October 2026 in Circulation: Heart Failure
Verified
Journal Article
Closed access
LLLirong Lu
Lirong Lu
SKSabrina Abou Kamar
Sabrina Abou Kamar
CPConstantin Laurent Palm
Constantin Laurent Palm
NSNiels Tjeerd Benjamin Scholte
Niels Tjeerd Benjamin Scholte
Navin Suthahar MD, MSc, PhD, FESC, FHFANavin Suthahar MD, MSc, PhD, FESC, FHFA
Navin Suthahar MD, MSc, PhD, FESC, FHFA
IKIsabella Kardys
Isabella Kardys
BACKGROUND: Heart failure (HF) involves complex metabolic and lipid-related disturbances. While prior studies have shown that static lipid and metabolic profiles are associated with poor prognosis in chronic stable HF, it remains unclear whether serially measured lipid and metabolic biomarkers are associated with adverse outcomes. METHODS: We analyzed longitudinal data from 2 independent HF cohorts with serial blood sampling (Bio-SHiFT [Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis] and TRIUMPH [Translational Initiative on Unique and Novel Strategies for Management of Patients With Heart Failure]), using nuclear magnetic resonance spectroscopy to quantify 45 circulating metabolic biomarkers. Joint models, combining linear mixed-effects models for repeated biomarker measurements with Cox proportional hazards models for time-to-event outcomes, were used to assess associations between current levels of serially measured biomarkers and the cohort-specific primary end point, defined as a composite of HF hospitalization, advanced HF therapy, or cardiovascular death. Models were adjusted for relevant clinical covariates. RESULTS: The Bio-SHiFT cohort (N=382; mean age, 63±13 years; 73% men; 72% New York Heart Association class I–II) contributed 2956 serial nuclear magnetic resonance measurements, while the TRIUMPH cohort (N=233; mean age 69±13 years; 69% men; 21% New York Heart Association class I–II) contributed 666. Multiple lipid-related biomarkers, including lipoprotein particle concentration, size, and standard lipid components, were associated with the primary end point. Findings were consistent between the 2 cohorts. Among high-density lipoprotein-related measures, higher current levels of S-high-density lipoprotein particle (hazard ratio [95% CI] for Bio-SHiFT per Z score of natural log-transformed biomarker, 0.59 [0.45–0.78]), high-density lipoprotein subclass 2 particle (0.57 [0.42–0.80]), and total high-density lipoprotein particle (0.54 [0.41–0.70]) were consistently associated with lower risk, whereas greater mean high-density lipoprotein particle size (1.52 [1.23–1.87]) was associated with higher risk. In addition, higher current levels of medium-triglyceride-rich lipoprotein particle, total triglycerides, triglyceride-rich lipoprotein cholesterol, triglyceride-rich lipoprotein total triglycerides, and ApoA-I (apolipoprotein AI) were associated with lower risk. Beyond lipid-related biomarkers, higher current levels of the inflammation and metabolic dysregulation markers inflammation vulnerability index (3.11 [2.07–4.88]), metabolic malnutrition index (1.98 [1.38–2.96]), and metabolic vulnerability index (3.79 [2.43–5.98]) were associated with higher risk. CONCLUSIONS: Serially measured nuclear magnetic resonance-derived lipoprotein and metabolic biomarkers were associated with the primary end point in chronic stable HF. These findings support further evaluation of serial metabolic profiling as a complementary approach to risk assessment in HF.